Sonova stock carries 5.9 percent sales growth

Sonova stock carries 5.9 percent sales growth into September, with the shares trading at CHF 240.00 on SIX at 1:15 p.m. CEST on September 24, 2026. The price was down 0.83 percent from CHF 242.00, while the market capitalization stood at CHF 14,257,104,480.

Revenue sets the benchmark

Sonova reported group sales of CHF 3,605.9 million for fiscal year 2025/26, up 5.9 percent in local currencies, according to Sonova International in its May 18, 2026 results release. Growth reached 7.5 percent in the companys core hearing instruments business, giving the sales figure a stronger operating base than the group total alone suggests.

The latest full-year result also provides a clear comparison for the September quote. CHF 240.00 is CHF 8.00 below the 52-week high of CHF 248.00 and CHF 77.00 above the 52-week low of CHF 163.00, based on the same market snapshot.

AI platform adds a product catalyst

Sonovas Phonak brand launched the EON hearing aid platform on August 24, 2026. The platform combines the HYPERSONIC chip, Spheric Speech Clarity 3.0, AutoSense OS AI 8.0 and Made-For-All connectivity, according to the companys investor page.

The product matters because it links the reported growth rate to a specific commercial lever. Sonova describes itself as a global hearing care provider, while the EON portfolio targets speech understanding, scene intelligence and connectivity across several hearing aid formats.

Guidance frames the next checkpoint

In a September 17, 2026 earnings call transcript, Yahoo Finance reported that Sonova expects consolidated sales to rise 5 percent to 8 percent and core EBIT to grow 7 percent to 10 percent at constant exchange rates. Those ranges set a numerical hurdle above the 5.9 percent local-currency sales growth delivered in fiscal year 2025/26.

Stock stays below yearly high

Sonova stock was trading at CHF 240.00 on SIX on September 24, 2026 at 1:15 p.m. CEST. The combination of a CHF 14,257,104,480 market capitalization, a CHF 163.00 to CHF 248.00 52-week range and the 5.9 percent full-year sales increase puts the product launch and guidance range at the center of the next valuation discussion.